Xavier Daura Ribera

Xavier Daura Ribera

Universitat Autònoma de Barcelona

Life & Medical Sciences

I studied Biological Sciences at UAB, Barcelona, where I graduated in 1991 and obtained my PhD in 1996. I then moved to the laboratory of WF van Gunsteren at ETH Zurich, an international reference in the field of computational modeling and simulation of biomolecular systems. These were extraordinary years in which we performed seminal work on the simulation of polypeptide folding using molecular dynamics methods. In 2002 I was appointed ICREA Research Professor and returned with this position to the Institute of Biotechnology and Biomedicine (IBB) of the UAB, starting a group in Computational Biology. Today, our work is primarily concerned with the identification and development of new strategies to combat infections by multidrug-resistant bacteria, using computational and experimental approaches. I have also been an Adjunct Professor at the UAB since 2005 and, more recently, I have joined the CIBER-BBN (ISCIII). During the period 2011-2017 I served as Director of the IBB.

Research interests

The main objective of our research group is the development of new strategies to combat infections by multidrug-resistant (MDR) bacteria, in particular of the Gram-negative (GN) group. The increasing emergence and spread of MDR pathogens constitutes at present one of the major threats to public health. The shortage of effective antimicrobials for the treatment of MDR GN infections is particularly critical as cases of pan-resistance are not uncommon. The discovery of new drug targets and modes of action (MoA), less prone to the development of resistance, has therefore become a pressing need. In parallel, the development of effective vaccines may offer a solution for high-risk population groups. Our team combines a range of computational and experimental techniques for the identification of antimicrobial-target candidates with new MoA and vaccine candidates eliciting prescribed resposes. Much of this work is done in collaboration with the group of Bacterial Molecular Genetics of IBB.

Selected publications

- Gómez AC, Horgan C, Yero D, Bravo M, Daura X, O'Driscoll M, Gibert I & O'Sullivan TP 2023, 'Synthesis and evaluation of aromatic BDSF bioisosteres on biofilm formation and colistin sensitivity in pathogenic bacteria', Eur J Med Chem, 261, 115819.
- Coto-Segura P, Segú-Vergés C, Martorell A, Moreno-Ramírez D, Jorba G, Junet V, Guerri F, Daura X, Oliva B, Cara C, Suárez-Magdalena O, Abraham S & Mas JM 2023, 'A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis', Front Immunol, 14, 1212981.
- Coves X, Bravo M, Huedo P, Conchillo-Solé O, Gómez AC, Esteve-Codina A, Dabad M, Gut M, Daura X, Yero D & Gibert I 2023, 'A Stenotrophomonas maltophilia TetR-Like Transcriptional Regulator Involved in Fatty Acid Metabolism Is Controlled by Quorum Sensing Signals', Appl Environ Microbiol, 89(6):e0063523..
- Junet V, Matos-Filipe P, García-Illarramendi JM, Ramírez E, Oliva B, Farrés J, Daura X, Mas JM & Morales R 2023, 'A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status', CPT Pharmacometrics Syst Pharmacol, 12, 7, 916-928.

Selected research activities

Participation in EU Patent application EP23382593.4 'Klotho fusion protein and uses thereof'